{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:59:32Z","timestamp":1792652372803,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016253","name":"Atara Biotherapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA235667"],"award-info":[{"award-number":["R01 CA235667"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA236615-01"],"award-info":[{"award-number":["R01 CA236615-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA009501"],"award-info":[{"award-number":["T32CA009501"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["BC132124"],"award-info":[{"award-number":["BC132124"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA170630"],"award-info":[{"award-number":["CA170630"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA180889"],"award-info":[{"award-number":["CA180889"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["LC160212"],"award-info":[{"award-number":["LC160212"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009859","name":"Geoffrey Beene Cancer Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009859","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016228","name":"Derfner Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016228","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.omto.2021.06.006","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T01:41:31Z","timestamp":1623462091000},"page":"355-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Imaging CAR T-cell kinetics in solid tumors: Translational implications"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2704-3804","authenticated-orcid":false,"given":"Matthew S.","family":"Skovgard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1144-9818","authenticated-orcid":false,"given":"Hocine R.","family":"Hocine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmeen K.","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Moroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Y.","family":"Bellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srijita","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Morello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Ponomarev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Villena-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2021.06.006_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1158\/2326-6066.CIR-19-0801","article-title":"Tumor antigen heterogeneity: the \u201celephant in the room\u201d of adoptive T-cell therapy for solid tumors","volume":"8","author":"Albelda","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omto.2021.06.006_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: driving T\u00a0cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omto.2021.06.006_bib3","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3389\/fimmu.2020.01770","article-title":"The chimeric antigen receptor detection toolkit","volume":"11","author":"Hu","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omto.2021.06.006_bib4","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.omto.2021.06.006_bib5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T\u00a0cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2021.06.006_bib6","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T\u00a0cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2021.06.006_bib7","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omto.2021.06.006_bib8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omto.2021.06.006_bib9","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2021.06.006_bib10","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.06.006_bib11","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jtho.2018.10.167","article-title":"Pseudoprogression in previously treated patients with non\u2013small cell lung cancer who received nivolumab monotherapy","volume":"14","author":"Fujimoto","year":"2019","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.omto.2021.06.006_bib12","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2021.06.006_bib13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T\u00a0cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2021.06.006_bib14","doi-asserted-by":"crossref","first-page":"24275","DOI":"10.1073\/pnas.1903854116","article-title":"Long-term in\u00a0vivo microscopy of CAR T\u00a0cell dynamics during eradication of CNS lymphoma in mice","volume":"116","author":"Mulazzani","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2021.06.006_bib15","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1158\/1078-0432.CCR-10-0192","article-title":"Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T\u00a0cells genetically targeted to the MUC16 antigen","volume":"16","author":"Chekmasova","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2021.06.006_bib16","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T\u00a0cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omto.2021.06.006_bib17","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified t-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2021.06.006_bib18","doi-asserted-by":"crossref","first-page":"CT036","DOI":"10.1158\/1538-7445.AM2019-CT036","article-title":"Abstract CT036. A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T\u00a0cells: safety and efficacy","volume":"79","author":"Adusumilli","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2021.06.006_bib19","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1200\/JCO.2019.37.15_suppl.2511","article-title":"Regional delivery of mesothelin-targeted CAR T\u00a0cells for pleural cancers: safety and preliminary efficacy in combination with anti-PD-1 agent","volume":"37","author":"Adusumilli","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.06.006_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor-engineered T\u00a0cells effectively targets HER2+ breast cancer metastasis to the brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2021.06.006_bib21","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.3389\/fimmu.2018.02268","article-title":"Effective targeting of TAG72+ peritoneal ovarian tumors via regional delivery of CAR-engineered T\u00a0cells","volume":"9","author":"Murad","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omto.2021.06.006_bib22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2967\/jnumed.116.177857","article-title":"Preclinical pharmacokinetics and biodistribution studies of 89Zr-labeled pembrolizumab","volume":"58","author":"England","year":"2017","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.omto.2021.06.006_bib23","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.2967\/jnumed.114.153338","article-title":"Immuno-PET of murine T\u00a0cell reconstitution postadoptive stem cell transplantation using anti-CD4 and anti-CD8 cys-diabodies","volume":"56","author":"Tavar\u00e9","year":"2015","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.omto.2021.06.006_bib24","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2021.06.006_bib25","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2021.06.006_bib26","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2021.06.006_bib27","doi-asserted-by":"crossref","first-page":"14342","DOI":"10.1073\/pnas.0804105105","article-title":"Visualizing fewer than 10 mouse T\u00a0cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer","volume":"105","author":"Rabinovich","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2021.06.006_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jtho.2017.10.001","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies","volume":"13","author":"Kiesgen","year":"2018","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.omto.2021.06.006_bib29","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00109-011-0764-0","article-title":"Animal models and molecular imaging tools to investigate lymph node metastases","volume":"89","author":"Servais","year":"2011","journal-title":"J.\u00a0Mol. Med. (Berl.)"},{"key":"10.1016\/j.omto.2021.06.006_bib30","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T\u00a0cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2021.06.006_bib31","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3389\/fimmu.2020.01503","article-title":"Commentary: long-term in\u00a0vivo microscopy of CAR T\u00a0cell dynamics during eradication of CNS lymphoma in mice","volume":"11","author":"Hocine","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omto.2021.06.006_bib32","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T\u00a0cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2021.06.006_bib33","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omto.2021.06.006_bib34","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e318270dec7","article-title":"Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T\u00a0cells manufactured at clinical scale","volume":"35","author":"Wang","year":"2012","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omto.2021.06.006_bib35","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/s41467-018-03524-1","article-title":"Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells","volume":"9","author":"Emami-Shahri","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omto.2021.06.006_bib36","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nm.1930","article-title":"Sensitive in\u00a0vivo imaging of T\u00a0cells using a membrane-bound Gaussia princeps luciferase","volume":"15","author":"Santos","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2021.06.006_bib37","doi-asserted-by":"crossref","first-page":"eaaw5096","DOI":"10.1126\/sciadv.aaw5096","article-title":"Imaging CAR T\u00a0cell therapy with PSMA-targeted positron emission tomography","volume":"5","author":"Minn","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omto.2021.06.006_bib38","doi-asserted-by":"crossref","first-page":"14007","DOI":"10.1038\/mto.2014.7","article-title":"Molecular imaging of oncolytic viral therapy","volume":"1","author":"Haddad","year":"2015","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2021.06.006_bib39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1593\/neo.07981","article-title":"Utility of a herpes oncolytic virus for the detection of neural invasion by cancer","volume":"10","author":"Gil","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.omto.2021.06.006_bib40","doi-asserted-by":"crossref","first-page":"e77065","DOI":"10.1371\/journal.pone.0077065","article-title":"Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens","volume":"8","author":"Walters","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omto.2021.06.006_bib41","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1021\/bc0498572","article-title":"Multimodality in\u00a0vivo molecular-genetic imaging","volume":"15","author":"Doubrovin","year":"2004","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.omto.2021.06.006_bib42","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nbt805","article-title":"Serial in\u00a0vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes","volume":"21","author":"Koehne","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omto.2021.06.006_bib43","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11307-016-0981-6","article-title":"Comparative analysis of human nucleoside kinase-based reporter systems for PET imaging","volume":"19","author":"Lee","year":"2017","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.omto.2021.06.006_bib44","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1182\/blood-2005-04-1366","article-title":"Human CD8+ T\u00a0cells store CXCR1 in a distinct intracellular compartment and up-regulate it rapidly to the cell surface upon activation","volume":"106","author":"Gasser","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.omto.2021.06.006_bib45","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.4049\/jimmunol.1300523","article-title":"T lymphocytes sense antigens within seconds and make a decision within one minute","volume":"191","author":"Brodovitch","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omto.2021.06.006_bib46","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1038\/ncomms8458","article-title":"Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints","volume":"6","author":"Mikucki","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omto.2021.06.006_bib47","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.bbrc.2017.06.072","article-title":"Intratumoral injection of IFN-\u03b2 induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb","volume":"490","author":"Uehara","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omto.2021.06.006_bib48","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3389\/fimmu.2019.00333","article-title":"Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy","volume":"10","author":"Vilgelm","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omto.2021.06.006_bib49","doi-asserted-by":"crossref","first-page":"e56554","DOI":"10.7554\/eLife.56554","article-title":"Cytotoxic T\u00a0cells swarm by homotypic chemokine signalling","volume":"9","author":"Galeano Ni\u00f1o","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.omto.2021.06.006_bib50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.it.2003.12.005","article-title":"Chemokines: multiple levels of leukocyte migration control","volume":"25","author":"Moser","year":"2004","journal-title":"Trends Immunol."},{"key":"10.1016\/j.omto.2021.06.006_bib51","doi-asserted-by":"crossref","first-page":"e0223814","DOI":"10.1371\/journal.pone.0223814","article-title":"Feasibility of real-time in\u00a0vivo 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging","volume":"15","author":"Lee","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omto.2021.06.006_bib52","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.2967\/jnumed.107.047324","article-title":"Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging","volume":"49","author":"Dobrenkov","year":"2008","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.omto.2021.06.006_bib53","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.7150\/jca.44413","article-title":"Comprehensive analysis of the tumor microenvironment in cutaneous melanoma associated with immune infiltration","volume":"11","author":"Wang","year":"2020","journal-title":"J.\u00a0Cancer"},{"key":"10.1016\/j.omto.2021.06.006_bib54","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/annonc\/mdz207","article-title":"Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer","volume":"30","author":"Kudo","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omto.2021.06.006_bib55","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jtho.2015.12.104","article-title":"Adaptive neoadjuvant chemotherapy guided by (18)F-FDG PET in resectable non-small cell lung cancers: the NEOSCAN trial","volume":"11","author":"Chaft","year":"2016","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.omto.2021.06.006_bib56","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/RTI.0000000000000219","article-title":"Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective","volume":"31","author":"Dimou","year":"2016","journal-title":"J.\u00a0Thorac. Imaging"},{"key":"10.1016\/j.omto.2021.06.006_bib57","doi-asserted-by":"crossref","first-page":"7924","DOI":"10.7150\/thno.37924","article-title":"Imaging of T-cells and their responses during anti-cancer immunotherapy","volume":"9","author":"Krekorian","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.omto.2021.06.006_bib58","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.tibtech.2017.03.012","article-title":"In\u00a0vivo molecular bioluminescence imaging: new tools and applications","volume":"35","author":"Mezzanotte","year":"2017","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.omto.2021.06.006_bib59","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2967\/jnumed.115.159855","article-title":"Comparative analysis of t\u00a0cell imaging with human nuclear reporter genes","volume":"56","author":"Moroz","year":"2015","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.omto.2021.06.006_bib60","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1089\/scd.2012.0608","article-title":"Engineered human embryonic stem cell-derived lymphocytes to study in\u00a0vivo trafficking and immunotherapy","volume":"22","author":"Knorr","year":"2013","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.omto.2021.06.006_bib61","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.3389\/fimmu.2018.03097","article-title":"A dual-color bioluminescence reporter mouse for simultaneous in\u00a0vivo imaging of t\u00a0cell localization and function","volume":"9","author":"Kleinovink","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omto.2021.06.006_bib62","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/S0959-8049(02)00390-8","article-title":"PET imaging of gene expression","volume":"38","author":"Blasberg","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omto.2021.06.006_bib63","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MNM.0000000000000789","article-title":"18F-Fluorodeoxyglucose PET\/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma","volume":"39","author":"Hall","year":"2018","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.omto.2021.06.006_bib64","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ncponc1278","article-title":"Noninvasive detection of therapeutic cytolytic T\u00a0cells with 18F-FHBG PET in a patient with glioma","volume":"6","author":"Yaghoubi","year":"2009","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.omto.2021.06.006_bib65","doi-asserted-by":"crossref","first-page":"eaag2196","DOI":"10.1126\/scitranslmed.aag2196","article-title":"Reporter gene imaging of targeted T\u00a0cell immunotherapy in recurrent glioma","volume":"9","author":"Keu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omto.2021.06.006_bib66","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1172\/JCI77326","article-title":"Noninvasive detection of tumor-infiltrating T\u00a0cells by PET reporter imaging","volume":"125","author":"McCracken","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2021.06.006_bib67","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2967\/jnumed.109.074344","article-title":"A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs","volume":"51","author":"Likar","year":"2010","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.omto.2021.06.006_bib68","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1172\/JCI98509","article-title":"Imaging activated T\u00a0cells predicts response to cancer vaccines","volume":"128","author":"Alam","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2021.06.006_bib69","doi-asserted-by":"crossref","first-page":"11959","DOI":"10.1158\/0008-5472.CAN-07-1250","article-title":"In\u00a0vivo imaging and quantitation of adoptively transferred human antigen-specific T\u00a0cells transduced to express a human norepinephrine transporter gene","volume":"67","author":"Doubrovin","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2021.06.006_bib70","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2967\/jnumed.106.037812","article-title":"Imaging hNET reporter gene expression with 124I-MIBG","volume":"48","author":"Moroz","year":"2007","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.omto.2021.06.006_bib71","doi-asserted-by":"crossref","first-page":"e90064","DOI":"10.1172\/jci.insight.90064","article-title":"Longitudinal PET imaging demonstrates biphasic CAR T\u00a0cell responses in survivors","volume":"1","author":"Vedvyas","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.omto.2021.06.006_bib72","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1039\/c2ib20093g","article-title":"Imaging of genetically engineered T\u00a0cells by PET using gold nanoparticles complexed to Copper-64","volume":"5","author":"Bhatnagar","year":"2013","journal-title":"Integr. Biol."},{"key":"10.1016\/j.omto.2021.06.006_bib73","doi-asserted-by":"crossref","first-page":"12457","DOI":"10.1073\/pnas.0704460104","article-title":"In\u00a0vivo imaging of T\u00a0cell delivery to tumors after adoptive transfer therapy","volume":"104","author":"Pittet","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2021.06.006_bib74","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00262-007-0355-7","article-title":"Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer","volume":"57","author":"Bernhard","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omto.2021.06.006_bib75","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1600-0609.1989.tb00112.x","article-title":"Tumour imaging of indium-111 oxine-labelled autologous lymphocytes as a staging method in Hodgkin\u2019s disease","volume":"42","author":"Grimfors","year":"1989","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.omto.2021.06.006_bib76","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1200\/JCO.1989.7.2.250","article-title":"Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma","volume":"7","author":"Fisher","year":"1989","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.06.006_bib77","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.2967\/jnumed.118.208041","article-title":"Antibody with infinite affinity for in\u00a0vivo tracking of genetically engineered lymphocytes","volume":"59","author":"Krebs","year":"2018","journal-title":"J.\u00a0Nucl. Med."}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770521000851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770521000851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:23:25Z","timestamp":1762496605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770521000851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":77,"alternative-id":["S2372770521000851"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2021.06.006","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging CAR T-cell kinetics in solid tumors: Translational implications","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2021.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors.","name":"copyright","label":"Copyright"}]}}